Last reviewed · How we verify
TRK-820
At a glance
| Generic name | TRK-820 |
|---|---|
| Also known as | Nalfurafine Hydrochloride |
| Sponsor | Toray Industries, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans (NA)
- Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP (PHASE4)
- Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis (NA)
- Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis (PHASE2)
- A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet (PHASE3)
- Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
- TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus (PHASE1)
- Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRK-820 CI brief — competitive landscape report
- TRK-820 updates RSS · CI watch RSS
- Toray Industries, Inc portfolio CI